Print Page    E-mail Page    RSS    E-mail Alerts 

RSS Content

Bellerophon Therapeutics to Present at Rodman & Renshaw 20th Annual Global Investment Conference

WARREN, N.J., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that Fabian Tenenbaum, Chief Executive Officer, will provide a corporate overview at the Rodman & Renshaw 20th Annual Global Investment Conference, taking place September 4-6, 2018, at the St. Regis New York Hotel.

Bellerophon Presentation Details
Date:  Wednesday, September 5
Time:  9:10am Eastern Time
Location:  The St. Regis New York Hotel, Fontainebleau Foyer, New York, NY
Webcast:  http://wsw.com/webcast/rrshq28/blph/

About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing multiple product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system.  For more information, please visit www.bellerophon.com.

Contact
Bellerophon Therapeutics
Fabian Tenenbaum, Chief Executive Officer
(908) 574-4767

LifeSci Advisors
Brian Ritchie
212-915-2578
britchie@lifesciadvisors.com

Primary Logo

Bellerophon Therapeutics, Inc.